Evaluating KL-6 levels in lung disease related to rheumatoid arthritis
Value of Krebs Von Den Lungen-6 Assay in Rheumatoid Artheritis-associated Interstitial Lung Disease
This study is testing if measuring KL-6 levels in the blood can help doctors better understand and treat lung problems in people with rheumatoid arthritis.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 80 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Assiut University Academic / other |
| Locations | 1 site (Assiut) |
| Trial ID | NCT05979454 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the serum levels of Krebs von den Lungen-6 (KL-6) in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). KL-6 is a glycoprotein that serves as a marker for pulmonary epithelial cell injury and has been associated with disease severity in various interstitial lung diseases. The study will assess the potential of KL-6 as a diagnostic and prognostic tool specifically for RA-ILD, which is a significant cause of morbidity and mortality in patients with rheumatoid arthritis. By understanding KL-6 levels, the study seeks to improve monitoring and treatment responses for affected patients.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with rheumatoid arthritis who also have interstitial lung disease.
Not a fit: Patients with rheumatoid arthritis who do not have interstitial lung disease or those with evidence of infection will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a valuable diagnostic and prognostic tool for managing lung disease in rheumatoid arthritis patients.
How similar studies have performed: Previous studies have shown KL-6 to be a valuable marker in other interstitial lung diseases, suggesting potential success in this novel application for RA-ILD.
Eligibility criteria
Show full inclusion / exclusion criteria
Diagnosis of RA will be based on American College of Rheumatology/European League against Rheumatism (ACR-EULAR) classification criteria 2010. Inclusion Criteria: * all patients have rheumatoid arthritis-associated interstitial lung disease Exclusion Criteria: * Patients with any evidence of infection will be excluded.
Where this trial is running
Assiut
- Safaa A Eid — Assiut, Egypt (Recruiting)
Study contacts
- Principal investigator: Safaa A Eid, Fellow — Assiut University
- Study coordinator: Safaa A Eid, Fellow
- Email: safaa_gayed@aun.edu.eg
- Phone: +20 01002569966
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.